Other equities research analysts have also recently issued reports about the company. BidaskClub upgraded Intrexon Corporation from a sell rating to a hold rating in a report on Thursday, June 22nd. Zacks Investment Research upgraded Intrexon Corporation from a hold rating to a buy rating and set a $24.00 target price for the company in a report on Tuesday, May 2nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $37.60.
Shares of Intrexon Corporation (XON) traded down 1.82% during trading on Monday, hitting $17.30. The stock had a trading volume of 1,084,875 shares. The company’s market capitalization is $2.08 billion. The firm has a 50-day moving average price of $21.96 and a 200 day moving average price of $21.83. Intrexon Corporation has a 52 week low of $17.05 and a 52 week high of $32.90.
Intrexon Corporation (NYSE:XON) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. The company had revenue of $54.40 million during the quarter, compared to analysts’ expectations of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. Intrexon Corporation’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.42) EPS. Equities analysts anticipate that Intrexon Corporation will post ($0.87) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This article was reported by BNB Daily and is owned by of BNB Daily. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/19/intrexon-corporation-xon-pt-set-at-30-00-by-northland-securities-updated.html.
In other Intrexon Corporation news, CEO Randal J. Kirk acquired 132,625 shares of the company’s stock in a transaction on Friday, August 11th. The stock was acquired at an average price of $18.85 per share, for a total transaction of $2,499,981.25. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Andrew J. Last acquired 2,000 shares of the company’s stock in a transaction on Monday, August 14th. The stock was acquired at an average price of $19.99 per share, with a total value of $39,980.00. Following the acquisition, the chief operating officer now owns 2,000 shares in the company, valued at approximately $39,980. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 141,719 shares of company stock valued at $2,669,554. Company insiders own 55.10% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in Intrexon Corporation during the fourth quarter valued at $17,300,000. CWM LLC boosted its stake in Intrexon Corporation by 9,455.4% in the first quarter. CWM LLC now owns 35,546 shares of the biotechnology company’s stock valued at $705,000 after buying an additional 35,174 shares during the period. Private Advisor Group LLC boosted its stake in Intrexon Corporation by 18.6% in the first quarter. Private Advisor Group LLC now owns 35,502 shares of the biotechnology company’s stock valued at $672,000 after buying an additional 5,556 shares during the period. Capital Fund Management S.A. boosted its stake in Intrexon Corporation by 40.9% in the first quarter. Capital Fund Management S.A. now owns 127,798 shares of the biotechnology company’s stock valued at $2,533,000 after buying an additional 37,098 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in Intrexon Corporation by 60.0% in the first quarter. Goldman Sachs Group Inc. now owns 144,428 shares of the biotechnology company’s stock valued at $2,862,000 after buying an additional 54,179 shares during the period. Institutional investors and hedge funds own 84.52% of the company’s stock.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.